Recombinant KIR2DL2 (Lirilumab Biosimilar) antibody

Catalog No. ABIN7491003

The Human Monoclonal anti-KIR2DL2 (Lirilumab Biosimilar) antibody has been validated for FACS. It is suitable to detect KIR2DL2 (Lirilumab Biosimilar) in samples from Human.

Quick Overview for Recombinant KIR2DL2 (Lirilumab Biosimilar) antibody (ABIN7491003)

Target: KIR2DL2 (Lirilumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human

Clonality: Monoclonal

Conjugate: This KIR2DL2 (Lirilumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS)

Grade: Research Grade

Product Details anti-KIR2DL2 (Lirilumab Biosimilar) Antibody

Purpose: Anti-KIR2DL2 (lirilumab biosimilar) mAb

Characteristics: BMS-986015, IPH2102

Purification: Purified from cell culture supernatant by affinity chromatography

Isotype: IgG4

Application Details

Application Notes: Flow Cyt 1:100

Comment:

Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Reconstitute with deionized water

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Storage: -20 °C,-80 °C

Storage Comment: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Expiry Date: 12 months

Target Details for KIR2DL2 (Lirilumab Biosimilar)

Target: KIR2DL2 (Lirilumab Biosimilar)

Target Type: Biosimilar

Background: Synonyms: CD158b, CD158B1, NKAT-6, NKAT6, p58.2

UniProt: P43627